PAREXEL International is a biopharmaceutical contract research company that provides services to clients that enable them to bring new drugs to market. These services include strategy development, management of clinical trials, data management, biostatistical analysis, drug development consulting, and advanced eClinical technology solutions.
The company’s consulting segment, PAREXEL Consulting Services (PCS), handles the parts of drug development that are non-clinical: regulatory affairs and new product launches.
PAREXEL International trades publicly on the NASDAQ under the ticker symbol PRXL, is a member of the S&P 600, is a member of the Russell 2000, is #972 in the Fortune 1000, has 15,560 employees, and had $2 billion in revenue in 2014.
PAREXEL International
PAREXEL International is a biopharmaceutical contract research company that provides services to clients that enable them to bring new drugs to market. These services include strategy development, management of clinical trials, data management, biostatistical analysis, drug development consulting, and advanced eClinical technology solutions.
The company’s consulting segment, PAREXEL Consulting Services (PCS), handles the parts of drug development that are non-clinical: regulatory affairs and new product launches.
PAREXEL International trades publicly on the NASDAQ under the ticker symbol PRXL, is a member of the S&P 600, is a member of the Russell 2000, is #972 in the Fortune 1000, has 15,560 employees, and had $2 billion in revenue in 2014.
History
